BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15955124)

  • 21. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
    Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes.
    Iliadis F; Kadoglou NP; Hatzitolios A; Karamouzis M; Alevizos M; Karamitsos D
    In Vivo; 2007; 21(6):1107-14. PubMed ID: 18210765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor necrosis factor alpha -238G>A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitus.
    Fontaine-Bisson B; Wolever TM; Chiasson JL; Rabasa-Lhoret R; Maheux P; Josse RG; Leiter LA; Rodger NW; Ryan EA; El-Sohemy A
    Metabolism; 2007 May; 56(5):649-55. PubMed ID: 17445540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
    Tomazic J; Karner P; Vidmar L; Maticic M; Sharma PM; Janez A
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):99-105. PubMed ID: 16200335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance.
    Burgert TS; Duran EJ; Goldberg-Gell R; Dziura J; Yeckel CW; Katz S; Tamborlane WV; Caprio S
    Pediatr Diabetes; 2008 Dec; 9(6):567-76. PubMed ID: 18761646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Karakoç A; Törüner F; Bingöl B; Cakir N; Tiras B; Ayvaz G; Arslan M
    J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of lifestyle adjustment, metformin and rosiglitazone in polycystic ovary syndrome].
    Ma LK; Jin LN; Yu Q; Xu L
    Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):294-7. PubMed ID: 17673038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
    Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
    Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of metformin vs. placebo treatment on serum fatty acids in non-diabetic obese insulin resistant individuals.
    Rodríguez Y; Giri M; Feyen E; Christophe AB
    Prostaglandins Leukot Essent Fatty Acids; 2004 Dec; 71(6):391-7. PubMed ID: 15519498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
    Tamura Y; Watada H; Sato F; Kumashiro N; Sakurai Y; Hirose T; Tanaka Y; Kawamori R
    Diabetes Obes Metab; 2008 Sep; 10(9):733-8. PubMed ID: 17941868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postprandial variations of plasma inflammatory markers in abdominally obese men.
    Blackburn P; Després JP; Lamarche B; Tremblay A; Bergeron J; Lemieux I; Couillard C
    Obesity (Silver Spring); 2006 Oct; 14(10):1747-54. PubMed ID: 17062804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of metformin on insulin resistance in obese and hyperandrogenic women].
    Sir T; Castillo T; Muñoz S; López G; Calvillán M
    Rev Med Chil; 1997 Dec; 125(12):1457-63. PubMed ID: 9609021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of body fat distribution by waist circumference, dual-energy X-ray absorptiometry and ultrasonography to insulin resistance by homeostasis model assessment and lipid profile in obese and non-obese postmenopausal women.
    dos Santos RE; Aldrighi JM; Lanz JR; Ferezin PC; Marone MM
    Gynecol Endocrinol; 2005 Nov; 21(5):295-301. PubMed ID: 16373250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is postprandial hypertriglyceridaemia in relatives of type 2 diabetic subjects a consequence of insulin resistance?
    Kriketos A; Milner KL; Denyer G; Campbell L
    Eur J Clin Invest; 2005 Feb; 35(2):117-25. PubMed ID: 15667583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment options in insulin resistance obesity-related acanthosis nigricans.
    Romo A; Benavides S
    Ann Pharmacother; 2008 Jul; 42(7):1090-4. PubMed ID: 18492785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.
    Zwirska-Korczala K; Konturek SJ; Sodowski M; Wylezol M; Kuka D; Sowa P; Adamczyk-Sowa M; Kukla M; Berdowska A; Rehfeld JF; Bielanski W; Brzozowski T
    J Physiol Pharmacol; 2007 Mar; 58 Suppl 1():13-35. PubMed ID: 17443025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Postprandial changes of blood lipid after ordinary Chinese diet and the influencing factors thereof].
    Fu ZF; Liu ML
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):260-2. PubMed ID: 19552844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression.
    Moore GB; Pickavance LC; Briscoe CP; Clapham JC; Buckingham RE; Wilding JP
    Diabetes Obes Metab; 2008 Mar; 10(3):251-63. PubMed ID: 18269641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.